Complexa is a clinical stage biopharmaceutical company focused on transforming the treatment of fibrosis and inflammation-associated orphan diseases. Leveraging its differentiated endogenous nitrated fatty acid cell signaling technology, Complexa is advancing a platform of agents which target fibrosis and inflammation across multiple orphan disease indications. Complexa’s initial disease focus is on Focal Segmental Glomerulosclerosis (FSGS) and Pulmonary Arterial Hypertension (PAH), and development of other new chemical entities in its platform of cell signaling compounds. Unique and profound to the Company is the ability of its technology to not only halt, but to reverse disease related fibrosis. The Company’s lead product CXA-10 has completed human safety and proof of target engagement studies and moving into Phase 2 trials.

Complexa has over 100 published studies involving its technology covering many disease models from various international academic and industry collaborations. Complexa’s nitro and keto-fatty-acid anti-inflammatory human cell signaling technology stems from Nobel Prize winning research and a top 10 cited scientist in the field of biochemistry and pharmacology. The Company is led by highly experienced and prominent serial entrepreneurs in the healthcare industry.